Zavesca Actelion Pharmaceuticals - Treatment for Type 1 Gaucher Disease

Zavesca is in a class of drugs known as substrate reduction therapy (SRT), which reduces the amount of glycosphingolipid (GSL) production. Zavesca is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

Posted: July 2003

View comments

Hide
(web2)